These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8756742)

  • 1. [Activity of protein C in blood of patients with prostatic carcinoma].
    Iwan-Zietek I; Zietek Z; Kotschy M; Tyloch F; Zastawna E
    Pol Tyg Lek; 1996 Feb; 51(6-9):94-5. PubMed ID: 8756742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Activity of alpha 1-antitrypsin in blood of patients operated on for tumor and benign hyperplasia of the prostate].
    Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):77-8. PubMed ID: 8756736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Activity of alpha 1-antitrypsin in blood of patients with prostatic tumor].
    Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):89-90. PubMed ID: 8756740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The activity of alpha-2 macroglobulin in the blood of patients with prostatic carcinoma].
    Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F; Zastawna E
    Pol Merkur Lekarski; 1997 Jan; 2(9):196-8. PubMed ID: 10907027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor].
    Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):86-8. PubMed ID: 8756739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia].
    Povelitsa EA; Nabyrov EA
    Vopr Onkol; 2008; 54(5):596-601. PubMed ID: 19069473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5'-nucleotidase activity in prostatic carcinoma and benign prostatic hyperplasia.
    Rackley RR; Lewis TJ; Preston EM; Delmoro CM; Bradley EL; Resnick MI; Pretlow TP; Pretlow TG
    Cancer Res; 1989 Jul; 49(13):3702-7. PubMed ID: 2471588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
    Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
    Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of epidermal growth factor in human benign prostatic hyperplasia and prostatic carcinoma and its prognostic significance.
    Shaikh N; Lai L; McLoughlin J; Clark D; Williams G
    Anticancer Res; 1990; 10(4):873-4. PubMed ID: 1696447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prolactin and prostate cancer. II. Blood levels of prolactin in prostatic tumors].
    Maganto Pavón E; Mayayo Dehesa T; Mateos Torres JA; Verdú Tartajo F; de Blas Gómez V; Romero Aguirre C
    Arch Esp Urol; 1982; 35(3):171-8. PubMed ID: 6181745
    [No Abstract]   [Full Text] [Related]  

  • 13. Haematological variables in prostatic carcinoma patients.
    Geenen RW; Delaere KP; van Wersch JW
    Acta Urol Belg; 1996 Sep; 64(3):21-6. PubMed ID: 8946777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum proteins of patients with benign hyperplastic and malignant prostate.
    Dhar NK; Dube PC; Chowdhury AR; Kar AB
    Indian J Cancer; 1973 Jun; 10(2):188-90. PubMed ID: 4129821
    [No Abstract]   [Full Text] [Related]  

  • 15. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis.
    Ren J; Huan Y; Wang H; Chang YJ; Zhao HT; Ge YL; Liu Y; Yang Y
    Clin Radiol; 2008 Feb; 63(2):153-9. PubMed ID: 18194690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression.
    Hara I; Miyake H; Yamanaka K; Hara S; Kamidono S
    Oncol Rep; 2002; 9(6):1379-83. PubMed ID: 12375052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of serum protein-bound sialic acid in benign and malignant prostatic growth: possible role of oxidative stress in sialic acid homeostasis.
    Goswami K; Nandeesha H; Koner BC; Nandakumar DN
    Prostate Cancer Prostatic Dis; 2007; 10(4):356-9. PubMed ID: 17404581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tissue plasminogen activator in urine of patients with prostatic carcinoma and benign prostatic hyperplasia].
    Zietek Z; Iwan-Zietek I; Kotschy M; Wolski Z; Kulwas A; Białkowska A
    Pol Merkur Lekarski; 1997 Apr; 2(10):266-7. PubMed ID: 9377662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence and structure of circulating immune complexes in patients with prostate tumors.
    Gołda R; Wolski Z; Wyszomirska-Gołda M; Madaliński K; Michałkiewicz J
    Med Sci Monit; 2004 Mar; 10(3):CR123-7. PubMed ID: 14976452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.